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Members of the IL-1 family play a key role in innate and adaptive immunity and in the patho-
genesis of diverse diseases. Members of IL-1R like receptor (ILR) family include signaling
molecules and negative regulators.The latter include decoy receptors (IL-1RII; IL-18BP) and
“receptors” with regulatory function (TIR8/SIGIRR; IL-1RAcPb; DIGIRR). Structural con-
siderations suggest that also TIGIRR-1 and IL-1RAPL may have regulatory function. The
presence of multiple pathways of negative regulation of members of the IL-1/IL-1R family
emphasizes the need for a tight control of members of this fundamental system.
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INTRODUCTION
IL-1R like receptors (ILRs) belong, together with Toll-like recep-
tors (TLRs), to a superfamily of phylogenetically conserved pro-
teins involved in innate immunity and inflammation (1–5). The
common characteristic of the members of this family is the pres-
ence of a conserved domain in the cytoplasmic region, called TIR
domain, originally defined as the Toll/IL-1-resistance and now
generally assumed as an acronym for Toll/IL-1R domain. The TIR
domain is involved in the activation of an evolutionarily conserved
signaling pathway leading to NF-kB translocation to the nucleus
and activation of protein kinases such as p38, c-Jun N-terminal
kinases (JNKs), extracellular signal-regulated kinases (ERKs), and
mitogen-activated protein kinases (mAPKs) (6). The ILR subfam-
ily includes the receptors and the accessory proteins (AcP) for
IL-1α (IL-1F1) and IL-1β (IL-1F2), IL-18/IL-1F4, IL-33/IL-F11,
and other IL-1 family members (IL-36α/IL-1F6, IL-36β/IL-1F8,
and IL-36γ/IL-1F9), which are involved in the initiation of an
amplification cascade of innate resistance and inflammation and
contribute to the activation and orientation of adaptive immu-
nity (7–9). Some members of the family remain orphan receptors
with still unknown ligands and functions. For instance, in the IL-
1R subfamily, TIR8/SIGIRR, TIGIRR-1, and IL-1RAPL have no
characterized ligands so far (2, 10, 11).
The activation of the ILR-dependent signaling cascade is tightly
regulated. Indeed, the deregulated activation of these receptors,
which lead to the production of proteins related to inflammation
and immunity, potentially mediates damaging local and systemic
inflammatory reactions. Several pathological conditions depend,
at least in part, on the inflammatory potential of the IL-1 family
members mentioned above. For instance, the IL-1 system rep-
resents a relevant therapeutic target in arthritis, type 2 diabetes,
psoriasis, sepsis, ischemia and reperfusion, atherosclerosis, graft
rejection, cancer (12–15). The regulatory mechanisms identified
so far in the IL-1 system (ligands, receptors, signaling pathway)
act extracellularly or intracellularly (16, 17). IL-1R antagonists
(IL-1Ra)/IL-1F3 and IL-36Ra/IL-1F5 are polypeptide antagonists
competing with IL-1 and IL-36α/IL-1F6, IL-36β/IL-1F8, and IL-
36γ/IL-1F9, respectively, for receptor binding (3, 7, 18–20). IL-1RII
lacks a signaling domain and by binding IL-1 prevents its inter-
action with a signaling receptor complex and therefore acts as a
decoy, dominant-negative molecule, and scavenger. The negative
regulator of ILR and TLR signaling, TIR8 (also known as SIGIRR),
acts intracellularly. IRAK-M and MyD88s are intracellular nega-
tive regulators of ILRs and TLRs signaling (21, 22). Finally, ILR or
TLR signaling proteins or transcription factors are targets of miR-
NAs, such as miR-155, miR-21, miR-146a, miR-132, miR-9, and
miR-147, whose transcription is induced by inflammatory medi-
ators [lipopolysaccharide (LPS), TNFα, IL-1 β] through NF-kB
(23–25).
Here, we summarize our current understanding of the structure
and function of negative regulatory receptors of the ILR family, in
particular IL-1RII, which has served to defining the decoy recep-
tor paradigm, and TIR8/SIGIRR, focusing on their regulatory roles
in different pathological disorders dependent on ILRs and TLRs
activity, and finally describe other largely uncharacterized mem-
bers of the family with a negative regulatory potential, TIGIRR-1,
IL-1RAPL, IL-1RAPb.
THE DECOY RECEPTOR IL-1RII
GENE AND PROTEIN
The first IL-1R was cloned from murine and human T cells,
whereas IL-1RII was identified soon after in B lymphocytes and
myelomonocytic cells (26, 27). On the basis of their structures,
IL-1RI and IL-1RII belong to the Ig-like superfamily of recep-
tors, with the extracellular portion containing 3 Ig-like domains.
The signaling IL-1R complex includes the type I IL-1 receptor
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(IL-1RI) and IL-1R AcP, which both have a cytoplasmic TIR
domain (Figure 1).
The gene encoding IL-1RII is located on chromosome 2 (q12–
22) in humans and in the centromeric region of chromosome 1 in
mice (28), in cluster with IL-1RI and other members of the family
(IL-33R, IL-18R, IL-36R). The type II receptor is highly conserved
in evolution and is found in bony fish, where it functions to inhibit
IL-1-induced inflammation (29). The third Ig domain of IL-1RII
is homologous to the Ig domain of IL-18BP (30) and indeed, it has
been suggested that IL-1RII and IL-18BP have a common ances-
tral gene and diverged at the level of fish (31). The IL-1RII locus
spans about 38 kb of genomic DNA, of which about 21 kb contains
the coding region. The exon structures of the extracellular por-
tion of IL-1RII and IL-1RI receptors are identical and amino acid
sequences share 28% homology. A single exon encodes the trans-
membrane region and a short cytoplasmic tail (29 amino acids) of
IL-1RII, which has no TIR domain and does not signal (Figure 1).
The human transcript encodes for a 386 amino acid glycosylated
protein of 68 kDa, in contrast with IL-1RI which is a 80–85 kDa
glycosylated protein and has a 213 amino acid cytoplasmic tail
containing a TIR domain responsible for signaling (32).
IL-1RII can be proteolytically processed and released in a sol-
uble form, via the actions of a metalloproteinase, A Disintegrin
and Metalloprotease 17 (ADAM17, also know as TACE) (33,
34). In addition, IL-1RII can be processed in a manner simi-
lar to Amyloid β protein precursor (APP), by alpha-, beta-, and
gamma-secretase: the ectodomain is shed in an alpha-secretase-
like manner, whereas the IL-1RII C-terminal fragment under-
goes further intramembrane proteolysis by gamma-secretase (35).
Finally, the aminopeptidase regulator of TNFR1 shedding (ARTS-
1) has been implicated in IL-1RII shedding in basal condi-
tion and upon cell stimulation with phorbol myristate acetate
(PMA) (36).
Wang et al. (37) solved the structure of IL-1 and IL-1RAcP in
complex with the extracellular domain of IL-1RII and showed that
the mode of interaction among IL-1β, IL-1RII, and IL-1RAcP and
the overall structure are extremely similar to those of the signaling
ligand-receptor complex (IL-1, IL-1R1, IL-1AcP).
MECHANISMS OF NEGATIVE REGULATION
Several lines of evidence are consistent with the view that the
IL-1RII is a bonafide IL-1 decoy.
FIGURE 1 | Mechanisms of negative regulation mediated by IL-1RII.
IL-1RII negatively regulates IL-1 responses in multiple ways. In
membrane-bound (1) or soluble form (2) IL-1RII acts as a decoy, capturing
with high-affinity IL-1β and IL-1α, but not IL-1ra, and preventing their
interaction with IL-1RI. IL-1RII acts as a dominant-negative influencing
IL-1RI-IL-1RAcp signaling receptor complex formation (3). The interaction
of ligand-bound soluble IL-1RII with soluble IL-1RAcP increases the
affinity for both IL-1α and IL-1β by about two orders of magnitude (4).
Finally, in cytosol soluble form, IL-1RII interacts with pro-IL-1α preventing
its pro-inflammatory activity during necrosis, until caspase-1 cleaves
IL-1RII and allows the secretion of IL-1α (5). Because of low affinity for
IL-1RII, IL-1ra does not compete with IL-1α and IL-1β for the interaction
with the decoy receptor (6), whereas it competes with IL-1α and IL-1β
antagonizing their interaction with the signaling receptor IL-1RI (7).
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A first level of control is represented by the differential affinity
of the signaling and decoy receptors for agonist or antagonist lig-
ands of the IL-1 family (Figure 1). IL-1RI binds IL-1α with higher
affinity than IL-1β (K d≈ 10−10 and 10−9 M, respectively) and IL-
1ra with an affinity similar to that for IL-1α. By contrast, IL-1RII
binds IL-1β and IL-1α with high affinity (K d≈ 10−9–10−10 and
10−8 M, respectively), but it binds IL-1ra at least 100 times less
efficiently (38). Plasmon resonance analysis revealed that IL-1β
has a slow off-rate from IL-1RII, whereas IL-1ra rapidly dissoci-
ates from IL-1RII but not from IL-1RI (39), in agreement with
the need that the two regulators of IL-1 do not bind each other
self defeating and frustrating their regulatory activity. By binding
agonist ligands with high affinity without inducing signaling, IL-
1RII acts as a molecular trap for IL-1 inhibiting its activity (27, 40)
(Figure 1).
Second, IL-1RII also forms a complex with IL-1 and the IL-
1RAcP. It therefore exerts a dominant-negative effect on the for-
mation of a signaling receptor complex, by sequestering AcP, which
is essential for signal transduction (41, 42) (Figure 1).
In addition, IL-1RII is also found in a soluble form, released
from cells via the actions of a metalloproteinase (see above).
Soluble IL-1RII is found in normal blood relatively at high concen-
trations, in the order of nanogram per milliliter. Cell-surface shed-
ding is the major mechanism responsible of soluble IL-1RII gener-
ation, but in addition an alternatively spliced transcript encoding
a soluble version of IL-1RII has been described (43). Soluble, but
not cell-associated, IL-1RII binds pro-IL-1β and blocks its process-
ing by IL-1-converting enzyme (ICE)/caspase-1 (38) (Figure 1).
Soluble AcP, encoded by an alternatively spliced mRNA (44) and
found at high levels in the circulation (300 ng/ml in humans), can
interact with ligand-bound soluble IL-1RII, enhancing the latter’s
affinity for IL-1α and IL-1β by two orders of magnitude, while not
affecting the very low affinity for IL-1Ra (40, 45) (Figure 1). In
mouse and monkey, the interaction between AcP and IL-1RII is
required for high-affinity binding of IL-1β and effective inhibition
(45). Thus, the interaction with AcP renders IL-1RII a much more
effective inhibitor of IL-1.
Finally, a further mechanism of negative control of IL-1α by IL-
1RII during necrosis has recently been proposed (46). The soluble
form of IL-1RII has been detected in the cytosol in large amounts,
possibly because the IL-1RII signal peptide is short and relatively
weak. In line with previous reports on systemic sclerosis fibrob-
lasts (47), in this cytosolic form, soluble IL-1RII interacts with
pro-IL-1α (Figure 1). This interaction protects pro-IL-1α from
cleavage by different enzymes (calpain, granzyme B, chymase, and
elastase) normally involved in the generation of the active form
(48, 49) and prevents IL-1α activity (46). This blockade would
be abrogated by active caspase-1 (for instance during infections),
which specifically cleaves IL-1RII, causing dissociation from IL-
1α, calpain processing, and complete restoration of IL-1α activity
after necrosis or during regulated secretion (Figure 1). Since IL-
1RII is expressed by a limited set of cell types, in contrast with
IL-1RI, which is widely expressed, this mechanism of negative
regulation would be cell type specific. Thus, the activity of IL-
1α during necrosis and sterile inflammation would be somehow
restricted to cell types which do not express IL-1RII. For instance,
the high inflammatory profile of vascular smooth muscle cells to
necrosis, which is IL-1α-dependent (50), would be in agreement
with low levels of IL-1RII. These findings would explain the tissue
specificity of inflammatory damage during necrosis.
The anti-inflammatory role of IL-1RII has been demonstrated
in different pathological conditions in animal models. Gene-
targeted mice overexpressing IL-1RII under the control of the
human keratin gene promoter were resistant to PMA-induced
chronic skin inflammation (51). Recombinant IL-1RII delivered
via implanted human keratinocytes overexpressing soluble IL-1RII
played a protective role in a mouse model of collagen-induced
arthritis (52) and intravenous administration of soluble IL-1RII
significantly reduced joint swelling and erosion in a model of
arthritis in rabbit (53). Gene transfer of a soluble IL-1RII-Ig
fusion protein reduced allograft rejection and prolonged graft sur-
vival in a rat model of heart transplantation, reduced infiltrating
macrophages, and CD4+ T cells, and lowered levels of TNF-α and
TGF-β (54). Similarly, IL-1RII ameliorated experimental autoim-
mune myocarditis by blocking IL-1 and inhibiting production of
the cytokines [IL-6, transforming growth factor-β, retinoic acid-
related orphan nuclear receptor (RORγt) and IL-17] involved in
the polarization of Th17 cells (55). Finally, in a mouse model of
endometriosis, consisting of human endometrial tissue implanted
in nude mice, human soluble IL-1-RII administered intraperi-
toneally reduced the growth and dissemination of endometrial
implants and the expression of IL-1β-dependent inflammatory,
angiogenic, and cell growth mediators (56).
In support of the view that IL-1RII is a professional anti-IL-1
molecule, Pox viruses have acquired and retained a soluble ver-
sion of type II IL-1R, that plays a key role in the regulation of
pathogenicity (57).
Thus, IL-1RII negatively regulates IL-1 responses in multi-
ple complementary ways. In membrane-bound or soluble form
IL-1RII acts as a decoy, capturing with high affinity IL-1, and
preventing it from interacting with IL-1RI. It acts as a dominant-
negative influencing IL-1RI-IL-1RAcp signaling receptor complex
formation. The interaction of ligand-bound soluble IL-1RII with
soluble IL-1RAcP increases the affinity for both IL-1α and IL-1β
by about two orders of magnitude and makes IL-1RII a powerful
inhibitor for both agonists. Finally, in cytosol soluble form, IL-1RII
interacts with pro-IL-1α preventing its pro-inflammatory activity
during necrosis.
EXPRESSION
In contrast with IL-1RI, which is expressed by a large variety
of cell types, IL-1RII is expressed by a limited set of cell types,
which also often express IL-1RI: among leukocytes, IL-1RII is
the predominant IL-1-binding protein found in monocytes, neu-
trophils, and B cells (26, 27, 40, 58). Monocyte differentiation to
macrophages, in particular M2 or M2-like macrophages, is asso-
ciated to increased expression of IL-1RII (58, 59). IL-1RII is also
expressed by microglial cells, in particular upon stimulation with
LPS and has been shown to regulate IL-1β actions by binding excess
levels of this cytokine during brain inflammation (60). In addition,
noradrenaline has been reported to upregulate IL-1RII in mixed
microglia via β-adrenoceptor activation and downstream activa-
tion of protein kinase A and ERK, thus preventing IL-1β-induced
neurotoxicity (61). Other stimuli involved in IL-1RII upregulation
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in the CNS include cerebral ischemia, kainic acid administration,
and central administration of IL-1β (62).
T regulatory cells (Tregs) have been shown to express sur-
face and soluble functional IL-1RII, as well as IL-1Ra mRNA.
This property has been exploited for the purification of activated
human FOXP3+ regulatory T cells from expansion cultures (63).
Activated human Tregs rapidly up-regulated IL-1RII and were able
to neutralize IL-1β, which suggests a physiological significance for
the expression of IL-1 decoy receptor on Tregs (64).
Differential levels of IL-1RII have been described in osteoclasts.
In particular, lower expression of IL-1RII has been detected in large
osteoclasts compared to small osteoclasts, and this is in line with
increased resorptive activity of large osteoclasts in response to IL-1
(65). IL-1RII is also expressed by basal epithelial cells of the skin
(66), epithelium of endometrium (67), vagina and urethra, and
chondrocytes. Endothelial cells and fibroblasts generally express
only IL-1RI and AcP.
Surface and soluble IL-1RII expression is strongly enhanced
by anti-inflammatory signals. Glucocorticoid hormones (GCs),
prostaglandins, the anti-inflammatory T helper 2 (Th2) cytokines
(IL-4 and IL-13), and IL-27 induced augmented surface expression
and release of IL-1RII in vitro, in particular in myelomonocytic
cells, and in vivo (27, 58, 68–72). In particular, IL-4 and dexam-
ethasone, by inducing IL-1RII, antagonized the prosurvival effect
of IL-1 in neutrophils in vitro (27). IL-10 increased circulating
soluble IL-1RII levels in vivo in mice. Aspirin increased IL-1RII
release from mononuclear cell cultures in vitro and in vivo (73).
IL-27 inhibited IL-1β-induced signaling in human macrophages
by downregulating the expression of the signaling receptor IL-
1RI, inducing expression of the receptor antagonist IL-1Ra, and
by upregulating the expression of the decoy receptor IL-1RII (72).
These data suggest that induction of IL-1RII contributes to the
anti-inflammatory effect of these mediators.
In contrast, pro-inflammatory molecules inhibit IL-1RII
expression. For instance, bacterial LPS caused a rapid shedding
of surface IL-1RII in monocytes, followed by down-regulation of
expression, whereas it stimulated the expression of IL-1RI,AcP and
the adapter protein MyD88 (74). Interferon γ (IFN-γ) inhibited
IL-1RII expression and release in myelomonocytic cells and coun-
teracted IL-4-dependent upregulation of IL-1RII (71). In addition
to LPS, chemoattractants such as formyl Meth-Leu-Phe (fMLP),
reactive oxygen intermediates (ROI), TNF, and PMA caused rapid
shedding of IL-1RII (33, 75, 76). PMA also induced alterna-
tively spliced soluble IL-1RAcP (44). Thus, shedding of IL-1RII
by circulating phagocytes and generation of alternatively spliced
soluble IL-1RAcP induced by chemoattractants in the early steps
of recruitment, could prepare cells to respond to IL-1 once they
enter tissues.
Acetylated low density (ac-LDL) and very low density (VLDL)
lipoprotein intracellular accumulation caused decreased IL-1RII
mRNA and protein expression in macrophages in vitro. In agree-
ment with these in vitro data, patients with familial combined
hyperlipidemia showed decreased expression of IL-1RII in mono-
cytes. Finally, IL-1RII expression in human atherosclerotic vessels
was defective compared to non-atherosclerotic arteries (77).
Naturally circulating levels of soluble IL-1R type II are in the
range of 5–10 ng/ml, although these can rise in certain chronic (78)
or acute (79) inflammatory settings (see below), in part reflecting
the activation of negative circuits of regulation of the cytokine
action.
IL-1RII IN HUMAN PATHOLOGICAL CONDITIONS: DIAGNOSTIC AND
THERAPEUTIC IMPLICATIONS
High levels of soluble IL-1RII are normally present in plasma
of healthy individuals. Defective or increased expression of tis-
sue or body fluid levels of soluble IL-1RII have been described
in diverse pathological conditions, ranging from critical condi-
tions to autoimmune diseases, neuroinflammatory diseases and
tumors.
Increased blood levels of soluble IL-1RII have been detected
in critically ill patients with infectious conditions such as sep-
sis, acute meningococcal infection, experimental endotoxemia,
operative trauma, or necrotizing enterocolitis in preterm infants
(73, 80, 81). In critically ill patients, IL-1RII levels were elevated
especially in severe, systemic infection and culture-positive infec-
tions. In patients with a marked systemic inflammatory response
syndrome, further pronounced increase of circulating IL-1RII lev-
els was observed in patients developing sepsis (80). Treatment
with glucocorticoids further increased IL-1RII levels, suggest-
ing that it potentially behaves as a biomarker for the activation
of anti-inflammatory pathways or for responsiveness to anti-
inflammatory agents. In acute meningococcal infections, increased
soluble IL-1RII levels correlated with disease severity, in partic-
ular with endotoxemia, complement-activation, and shock (82).
Increased IL-1RII levels were also observed in patients upon
treatment with aspirin (73).
IL-1Ra and/or IL-1RII increased levels were also detected in sera
of multiple sclerosis patients after steroid treatment for relapse
(83) and in the cerebrospinal fluid of patients with Alzheimer’s
disease, where it may be a marker of disease progression (84).
In psoriasis, IL-1ra and IL-1RII were both significantly overex-
pressed in the suprabasal and basal compartment, respectively, and
inversely correlated with the expressions of IL-1α (66). Increased
levels of soluble IL-1RII have been found in the synovial fluid
(39) and plasma of individuals with RA (78), and these nega-
tively correlated with severity of disease, suggesting IL-1RII acts
as natural antagonist of IL-1-driven joint destruction. In contrast,
plasma levels of IL-1Ra correlated positively with disease progres-
sion,possibly reflecting disease exacerbation (78). These data are in
line with experimental in vitro and in vivo data showing that over-
expression of IL-1RII in chondrocytes protected them from IL-1
stimulation (85), or that the transfer of cells overexpressing and
releasing IL-1RII resulted in the inhibition of collagen-induced
arthritis (52). These results, as well as the binding properties of
IL-1RII (high affinity for IL-1, low affinity for IL-1ra), supported
the development of IL-1RII as therapeutic molecule in rheumatoid
arthritis (see below). The expression of both receptors for IL-1 was
demonstrated by immunostaining and laser confocal microscopy
in sarcolemma from human muscle tissue samples, at higher levels
in patients with polymyositis and dermatomyositis as compared
with healthy individuals, together with increased expression of
IL-1α, IL-1β, and IL-1Ra (86).
IL-1RII is upregulated in some tumors, including pancreatic
ductal adenocarcinoma (87), prostatic cancer and benign prostatic
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hyperplasia (88), and ovarian cancer, where it provides a powerful
distinction between primary and recurrent tumors (89).
In contrast to these conditions associated to upregulation of
IL-1RII, in other contexts, defective expression of IL-1RII has
been associated to the pathogenesis of the disease. For instance,
gene-array analysis of osteoarthritic lesions indicated a lack of
expression of IL-1RII and IL-1ra (85), suggesting that defective
expression of negative regulators of the IL-1 system contributes
to pathogenesis. Similarly, endometriosis and endometrioid ovar-
ian cancer are associated with lower levels of serum and local
IL-1RII and with IL-1RII polymorphisms (90–92). In the context
of atherosclerosis, it has been proposed that, since macrophages
from hyperlipidemic patients have decreased IL-1RII mRNA and
protein expression, IL-1-dependent inflammation could be rel-
atively unchecked during atheroma formation (77). Genome-
wide association studies identified several candidate genes poten-
tially involved in inflammatory bowel disease (IBD) pathogenesis,
including IL-1RII (91).
Autoimmune inner ear disease is characterized by recurring
episodes of sudden or progressive sensorineural hearing loss.
Defective responsiveness to corticosteroid in this disease has been
correlated to the low induction of IL-1RII in peripheral blood
mononuclear cells (93).
Secretion of embryonic IL-1β is one of the first responses of
the blastocyst to the receptive endometrium. IL-1β is involved
in inducing molecular changes that are essential for attach-
ment of the blastocyst, such as immunomodulation, angiogenesis,
and endometrial tissue remodeling. In this context, it has been
proposed that these IL-1 activities are regulated by chorionic
gonadotropin, which acts directly on endometrial epithelial cells
to down-regulate the synthesis and release of IL-1RII (94).
The IL-1 decoy receptor IL-1RII was originally tested as a thera-
peutic by Amgen in arthritis, based on the promising results in this
context (45), but no clinical development of this agent has been
reported. Recently, the soluble IL-1RI (Rilonacept) was introduced
as therapeutic and approved by the FDA for selected autoinflam-
matory diseases, in particular cryopyrin-associated periodic syn-
dromes (familial cold autoinflammatory syndrome and Muckle–
Wells Syndrome) (95). The drug consists in a fusion protein
containing the extracellular domains of IL-1R1 and IL-1RAcP cou-
pled to the Fc region of human IgG1. Rilonacept acts similarly to
soluble IL-1RII, as a decoy, by binding IL-1β and IL-1αwith higher
affinity than IL-1Ra (96).
THE NEGATIVE REGULATOR TIR8/SIGIRR
GENE AND PROTEIN
TIR8/SIGIRR gene is localized on human chromosome 11 and
on murine chromosome 7 (97). The 410 amino acid-long protein
is constituted by a single Ig extracellular domain, a transmem-
brane domain, an intracellular conserved TIR domain, and a 95
amino acid-long tail at the C-terminal, reminiscent of the intracel-
lular tails of few ILR/TLR family members, in particular IL-1AcPb
and TIGIRR (see below) (Figure 2). Both in human and mouse,
TIR8/SIGIRR has several N- and O-glycosylation sites in the extra-
cellular domain (97, 98). The sequence and pattern of expression
of TIR8/SIGIRR is conserved among vertebrates, from chicken to
humans (99). In particular, human and mouse protein sequences
FIGURE 2 |TIR8/SIGIRR, a negative regulatory receptor of ILR and
TLR signaling. TIR8/SIGIRR is composed by a single extracellular Ig
domain, a transmembrane domain, an intracellular conserved TIR
domain and a long intracellular tail. Two replaced amino acid in the TIR
domain (Cys 222, Leu 305) are potentially involved in non-conventional
activation. TIR8/SIGIRR is an orphan receptor, but IL-36Ra has been
proposed as a TIR8/SIGIRR ligand in glial cells. TIR8/SIGIRR inhibits ILR
and TLR signaling by competing with MyD88 and IRAK recruitment at
the TIR domain thus dampening the signaling pathway leading to NF-kB
activation. In T cells and epithelial cells, TIR8/SIGIRR inhibits
IL-1-dependent activation of the Akt- mTOR pathway and of JNK, thus
controlling cell proliferation and survival. In vivo studies in gene-targeted
mice demonstrate that Tir8/Sigirr acts as a non-redundant negative
regulator in different inflammatory conditions dependent on ILRs or
TLRs.
share 82% homology. TIR8/SIGIRR is expressed in several tissues,
particularly in kidney, digestive tract, liver, lung, and lymphoid
organs (97, 100).
TIR8/SIGIRR proximal promoter has a binding site for
SP1, which enhances its transcription in basal conditions
(101). LPS stimulation reduces SP1 binding to TIR8/SIGIRR
promoter, possibly explaining the TIR8/SIGIRR down-regulation
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in inflammatory conditions (LPS administration, ulcerative colitis,
lung and urinary infections, infestations) (100–106). Recent stud-
ies demonstrated lower expression of TIR8/SIGIRR in fetal human
enterocytes providing a reasonable explanation to the excessive
inflammatory response in the immature intestine (107).
In contrast with these studies, TIR8/SIGIRR up-regulation
was shown in human monocytes during sepsis and ster-
ile systemic inflammation (108). Th2-lymphocytes expressed
higher levels of TIR8/SIGIRR compared to Th1 polarized or
non-differentiated lymphocytes (109). Pseudomonas aeruginosa
infected mice showed up-regulation of Tir8/Sigirr in the cornea,
macrophages, and Langerhans cells through the activity of vasoac-
tive intestinal peptide (110). Lactobacillus jensenii, a probi-
otic microorganism, induced up-regulation of TIR8/SIGIRR in
porcine Payer’s patch antigen presenting cells through activa-
tion of TLR2 (111). Similarly, LPS-induced Tir8/Sigirr in murine
Payer’s patch DCs, but not in spleen DCs (112). These data
suggest that Payer’s patch DCs use Tir8/Sigirr to tune TLRs
signaling.
MECHANISMS OF NEGATIVE REGULATION
The function of TIR8/SIGIRR consists in the specific inhibi-
tion of NF-kB and JNK activation following stimulation of
ILR or TLR family members (102, 113). TIR8 can modulate
the signal transduction activated by IL-1RI, IL-18R, T1/ST2,
TLR1/2, TLR3, TLR4, TLR7, and TLR9 (98, 102, 109, 113–115)
(Figure 2).
The extracellular Ig-like domain of TIR8/SIGIRR has been
show to interfere with the dimerization of IL-1RI and IL-1RAcP.
The cytoplasmic TIR domain binds TIR-containing adaptor mol-
ecules, which are no more available for signaling, whereas the
cytoplasmic tail is not involved in the inhibitory activity (102, 114).
A computational approach suggests a three-dimensional model for
the interaction among the TIR domains of TLR4, TLR7, MyD88,
and TIR8/SIGIRR. In this model, TIR8/SIGIRR binds TLR4 and
TLR7 through its BB-loop region preventing their dimerization
and MyD88 recruitment (116).
TIR8/SIGIRR can also regulate mTOR kinase activity in
Th17 lymphocytes (117) and in intestinal epithelial cells (118)
(Figure 2). These results are in agreement with the role of
TIR8/SIGIRR in autoimmune diseases and in tumor suppression
(see below).
ROLE OF TIR8/SIGIRR IN VIVO
Infection-associated inflammation
Tir8/Sigirr-deficient mice are more susceptible than wild type mice
in several infections, such as tuberculosis, candidiasis, aspergillosis,
P. aeruginosa infection, in terms of mortality and tissue dam-
age due to an exaggerated inflammatory response (103, 106, 119,
120) (Figure 2). Results obtained with IL-1-blocking antibodies
and IL-1RI-deficient mice indicated that in some of these infec-
tious conditions (tuberculosis and P. aeruginosa lung infection),
TIR8/SIGIRR played a major role in dampening inflammation
induced by IL-1R activation.
Similarly, in a colitis mouse model, Tir8/Sigirr-deficient mice
developed a more severe gut inflammation compared to wild
type mice (113, 121). Commensal microflora activates entero-
cyte TLRs and consequently induces survival of epithelial cells
and maintains gut homeostasis (122, 123). Lack of Tir8/Sigirr
in colon epithelial cells was shown to be associated to constitu-
tive NF-kB and JNK activation and up-regulated expression of
Cyclin D1 and Bcl-xL in homeostatic conditions, which returned
to the control level after depletion of commensal bacteria (121)
(Figure 2).
Excessive systemic inflammation was observed in Tir8/Sigirr-
deficient mice upon LPS challenge, and reduced inflammation
and mortality were described in Tir8/Sigirr overexpressing mice
in LPS-dependent acute lung injury model (102, 124). However,
these phenotypes possibly depend on the genetic background since
excessive systemic or local inflammatory reactions to LPS were not
confirmed in other studies (102, 113).
In contrast with these data, in a urinary tract infection model,
Tir8/Sigirr inhibited an effective host response against uropatho-
genic E. coli, as indicated by lower renal bacterial load and dysfunc-
tion in TIR8-deficient mice, associated to increased circulating and
intrarenal neutrophils at the early phase of infection (125).
Sterile inflammatory conditions
Recent data suggest that TIR8/SIGIRR plays a direct role in
inhibiting different IL-1-dependent signaling pathways, includ-
ing IL-1R-mTOR, in Th17 lymphocytes, thus tuning initial Th17
differentiation and preventing Th17 cell-mediated pathogenic
effects (117) (Figure 2). This effect was particularly evident in
the control of CNS autoimmune inflammation in a model of
experimental autoimmune encephalomyelitis (117). Tir8/Sigirr
deficiency was also associated to increased susceptibility to develop
autoimmunity in a model of systemic lupus erythematosus
(B6lpr/lpr), as well as in a model of lupus nephritis induced
by hydrocarbon oil (pristane) (115, 126). In the lpr/lpr model,
Tir8/Sigirr deficiency was responsible for massive lymphoprolif-
eration, peribronchial inflammation, and mesangio-proliferative
glomerulonephritis, due to B and dendritic cell hyper-activation
in TLR7- and TLR9-dependent response to autoantigens and
nucleosomes (115). Tir8/Sigirr-deficient mice were also more
susceptible than wild type mice to both zymosan-induced and
collagen antibody-induced arthritis models, because of exces-
sive inflammation at least in part dependent on IL-1 (127)
(Figure 2).
In agreement with the results obtained in autoimmunity mouse
models, TIR8/SIGIRR was down modulated together with other
anti-inflammatory genes in psoriatic patients (128).
Studies on allergic inflammatory responses showed that
Tir8/Sigirr plays an important role also in controlling the axis
IL-33 – ST2 which is involved in Th2 cell polarization and Th2
cytokine production (109) (Figure 2).
DAMPs generated during renal ischemia/reperfusion are
responsible of the activation of intrarenal DCs, macrophages, and
neutrophils via TLRs and IL-1R, which are potentially involved
in post ischemic renal failure. In models of renal ischemia/
reperfusion or kidney transplantation, Tir8/Sigirr-deficient mice
showed increased renal injury or severe graft rejection,
respectively, associated to excessive cytokine and chemokine
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production and consequently, leukocyte recruitment and ampli-
fied adaptive immune response against donor antigens (129, 130)
(Figure 2).
Finally, in agreement with the expression in neurons, microglia,
and astrocytes (131), TIR8/SIGIRR was shown to be a modulator
of microglia activation by LPS, and of neuroinflammation (132).
Furthermore, Tir8/Sigirr-deficient mice showed impaired cogni-
tive and synaptic functions associated to up-regulated IL-1R1 and
TLR4 signaling in hippocampal tissue in response to IL-1α and
high mobility group box 1 (133). Studies on the anti-inflammatory
activity of IL-36Ra in the brain demonstrated at least a par-
tial involvement of TIR8/SIGIRR in down modulating glial cell
inflammatory responses through the production of IL-4 (18).
Cancer-related inflammation
Chronic inflammation is associated with promotion of malig-
nancy and tumor progression and several studies in animals have
shown the protumoral role of IL-1 in this context (134, 135). Along
the same line, in different murine models, TIR8/SIGIRR has been
demonstrated to play a key protective role in the pathogenesis
of cancer-related inflammation. In a model of colitis-associated
cancer (CAC), a colorectal disease that arises in patients suffering
from chronic IBD, Tir8/Sigirr-deficient mice were highly suscepti-
ble to both inflammation and carcinogenesis in terms of number,
size, and severity of lesions (121, 136) (Figure 2). The mechanism
proposed suggests that TIR8/SIGIRR plays a protective role prob-
ably by modulating the signaling activated by commensal bacteria
through TLRs in the epithelial cells and consequently, down-
stream events, including production of inflammatory mediators
and factors involved in cell survival and proliferation, leukocyte
recruitment, and angiogenesis (137). Moreover, Tir8/Sigirr defi-
ciency in the Apcmin/+ mouse model was associated to increased
intestinal lesion development due to higher Akt-mTOR activity,
a crucial tumorigenic pathway (118, 138). The data suggest that
Tir8/Sigirr exerts a tumor suppressor activity by controlling IL-
1- and TLR-induced mTOR-mediated cell cycle progression and
consequent genetic instability (118).
In Chronic Lymphocytic Leukemia (CLL), human malignant
B cells express lower levels of TIR8/SIGIRR mRNA than nor-
mal B cells (139, 140). Similar results were found in the mouse
where CD19+ cells express lower levels of Tir8 messenger com-
pared to CD19+ cells isolated from a transgenic mouse model
of CLL (TCL1 mice) (141). In CLL, both genetic (e.g., MyD88
mutations) and micro environmental factors concur to the devel-
opment, expansion, and progression of the disease (139, 142). In a
murine CLL model, the absence of Tir8/Sigirr led to a more severe
and earlier appearance of monoclonal B-cell expansions and to
shortened life span. The disease mimicked the aggressive variant of
human CLL, characterized by the appearance of prolymphocytes
(141) (Figure 2), suggesting that TIR8/SIGIRR acts as an inhibitor
of CLL progression through a still unclear molecular mechanism.
OTHER ILR WITH NEGATIVE REGULATORY PROPERTIES
IL-18 BINDING PROTEIN
IL-18 binding protein (IL-18BP) is a secreted high affinity IL-18
binding molecule, which acts as a potent inhibitor of IL-18 and a
modulator of Th1 response. It is constituted by only one Ig-like
domain and it is structurally and functionally similar to IL-1RII
(30). Indeed, phylogenetic analysis suggests that IL-18BP and IL-
1RII had a common ancestral gene and diverged at the level of
fish (31). Recombinant IL-1F7 also binds to the IL-18BP, further
increasing the ability of IL-18BP to neutralize IL-18 activity (143).
Proteins homolog to IL-18BP have been found in poxviruses
(Ectromelia), which are responsible of neutralization of human
IL-18 during the viral infection and of dampening the inflamma-
tory response associated to the infection (144).
Further information about this molecule is available in the
review by Dinarello et al. in this issue.
IL-1RAcPb
The IL-1RAcP is the receptor subunit of the IL-1RI complex, and
it is also used by IL-36α/IL-1F6, IL-36β/IL-1F8 and IL-36γ/IL-1F9,
and IL-33 receptors. It has been shown that an alternative form of
AcP, called AcPb, can be generated by alternative splicing, in which
the prototypical AcP C-terminal exon 12 is skipped and an alter-
native exon 12b is used (145, 146). Smith et al. (146) characterized
this molecule and showed its regulatory properties in the brain.
The C-terminus encoded by these two alternative exons has 35%
amino acid identity, which includes conserved motifs of the TIR
domain. Moreover, the exon 12b encodes a sequence of approxi-
mately 140 additional amino acids in the C-terminal of the TIR
domain that has no homology to other protein sequences and is
of unknown function. The general structure of AcPb is similar
to that of AcP and suggests that the AcPb cytoplasmic domain is
similar to AcP TIR domain. However, there is one area of substan-
tial difference because of changed configuration in the DD loop
and aD helix regions of the AcPb TIR domain, which remembers
modification of TIR8/SIGIRR TIR domain, and altered charge
distribution pattern on its surface. It has been proposed that these
modifications could affect interaction with adapter and signaling
molecules. Indeed, AcPb is capable of forming a ligand-dependent
complex with IL-1R, but it does not lead to the recruitment of
the adaptor molecules MyD88 and IRAK4 after stimulation with
IL-1, and is unable to mediate specific IL-1 responses. In both
human and mouse, the expression of the AcPb is restricted to
the CNS (whole brain, fetal brain, cerebellum, and spinal cord).
AcP and AcPb are coexpressed in the same cells, but AcPb is the
more abundant isoform. It has been proposed that AcPb could
also be recruited to other AcP-utilizing receptors, such as ST2
and IL-1Rrp2/IL-36R, which are expressed in the CNS, once they
have bound their ligands (IL-33 and IL-36α,β,γ, respectively). In a
model of LPS challenge in the CNS, AcPb-deficiency was asso-
ciated to neuronal loss suggesting that AcPb may dampen the
neurotoxic effects of IL-1 by modulating the intracellular signaling
and gene expression response to LPS-induced IL-1, or possibly to
other cytokines acting through AcP (146). The inhibitory effect of
AcPb could depend on the failure to recruit MyD88 and IRAK4,
on the competition with AcP in a IL-1 receptor complex contain-
ing multiple IL-1R and AcP molecules, or on unknown functions
mediated by the C-terminal tail.
TIGIRR-1 AND IL-1RAPL
TIGIRR-1 and IL-1RAPL (also named TIGIRR-2) are local-
ized on the X chromosome and share between 22 and 48%
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overall identity to other ILR family members. IL-1RAPL and
TIGIRR-1 exons are spread out over a very large segment of
genomic DNA (more than 1500 kb for IL-1RAPL and 380 kb
for TIGIRR-1). Both TIGIRR-1 and IL-1RAPL contain a signal
peptide, three predicted extracellular Ig domains, a single trans-
membrane domain, and a highly conserved cytoplasmic region
containing a C-terminal cytoplasmic extension reminiscent of
the Drosophila Toll family, TIR8/SIGIRR, and AcPb cytoplasmic
domains.
A negative regulatory role has not yet been reported for
these two receptors. However, in in vitro studies performed
with chimeric molecules, the cytoplasmic domains of TIGIRR-
1 and IL-1RAPL fused to the extracellular and transmembrane
domains of IL-1RI or AcP could not induce NF-κB, similarly to
TIR8/SIGIRR, and in contrast with the cytoplasmic domains of
other members of the ILR family (10). Other functional stud-
ies showed that IL-1RAPL can activate JNK but not the ERK
or the p38 MAP kinases, whereas TIGIRR-1 cannot activate
JNK. Deletion mutagenesis studies showed that the activation of
JNK by IL-1RAPL does not depend on the integrity of its TIR
domain, suggesting a distinct mechanism of signaling through
this receptor (147).
TIGIRR-1 is highly conserved in human and mouse (94.5%
identical at the amino acid level) and it is expressed in skin,
liver, placenta, and fetal brain. IL-1RAPL, whose crystal struc-
ture has been determined (147), is expressed in heart, brain,
ovary, skin, and to a lesser extent in tonsil, fetal liver, prostate,
testis, small intestine, placenta, and colon. IL-1RAPL was iden-
tified as the gene responsible for hereditary non-syndromic
mental retardation and autism linked to chromosome region
Xp22.1–21.3 (148, 149). It is expressed in brain structures
involved in the hippocampal memory system, and it has a role
in brain development and function (150). No information are
available about a potential role of IL-1RAPL in inflammation
and defense, however, its C-terminal extension is reported to
interact with neuronal calcium sensor-1 and regulate neurite
outgrowth (150–152).
DIGIRR
Recently, a new member called DIGIRR was added to the ILR
family (153). DIGIRR was discovered in teleost fish and showed
high homology with TIR8/SIGIRR. DIGIRR is characterized by
an extracellular portion comprising two Ig-like domains, a trans-
membrane domain and TIR domain carrying two amino acid
substitutions (Arg419-Tyr420), which are responsible for the loss
of signaling. The DIGIRR mRNA was found expressed in several
tissues and in leukocytes and was upregulated by LPS, oppositely
to TIR8/SIGIRR, suggesting a different mechanism of response to
inflammatory stimuli between the two molecules. At the subcellu-
lar level, DIGIRR showed a peculiar distribution within the Golgi
apparatus.
Different lines of evidence suggest that DIGIRR acts as nega-
tive regulator of LPS- and IL-1β-induced inflammation. Indeed,
siRNA knock down of DIGIRR lead to increased production of IL-
β-induced pro-inflammatory cytokines in liver, kidney, and leuko-
cytes. Moreover, in vitro administration of DIGIRR to zebrafish
embryos significantly inhibited LPS- and IL-1β-induced activation
of NF-kB.
The discovery of DIGIRR could help to understand the evo-
lution of ILR family members. Indeed, the authors suggest the
hypothesis that DIGIRR and TIR8/SIGIRR derive from a com-
mon ancestral molecule that lost respectively one or two Ig-like
extracellular domains, and Ser or Arg-Tyr- amino acids in the TIR
domain. DIGIRR might represent an evolutionary intermediate
molecule between IL-1R and TIR8/SIGIRR, demonstrating a shift
from a potent receptor to a negative regulator.
CONCLUDING REMARKS
Studies conducted in the early 1990s suggesting that the non-
signaling IL-1RII acts as a molecular trap for the agonist and the
AcP, led to the formulation of the decoy paradigm, which has then
been extended to other cytokine families and chemokines. Decoy
receptors are now recognized as a general strategy to tune the
actions of primary inflammatory cytokines and chemokines.
The list of ILR/TLR family receptors acting as negative regula-
tors now includes TIR8/SIGIRR, which acts by modulating ILRs-
or TLRs-dependent signaling. In addition to these molecules,
soluble forms of signaling receptors or AcP act as decoys or
negative regulators by trapping the ligands. For instance, T1/ST2
exists also as a soluble isoform obtained by differential mRNA
processing, which acts as an antagonistic decoy receptor for IL-
33 (154), and has been proposed in the therapy of arthritis
(155). Similarly, soluble IL-1AcP, generated by alternative splic-
ing, forms a complex with IL-1β and IL-1RII playing a pro-
tective role in arthritis (156) and has been pharmacologically
exploited.
For several of these molecules further studies have to be per-
formed to unequivocally define their role in disease and their
potential as therapeutic targets. For instance, unfortunately there
are no genetic evidence on the consequence of IL-1RII-gene
deficiency or data supporting the relevance of TIR8/SIGIRR in
human disease. In addition, the clinical development of IL-RII
pharmacological targeting has not been reported. Finally, pharma-
cological approaches targeting TIR8/SIGIRR functions have not
been developed yet and they will be necessary to assess whether
TIR8/SIGIRR might be a therapeutic target in inflammatory
conditions.
However, the existence of IL-1RII, together with IL-1Ra,
TIR8/SIGIRR, brain AcPb, and other soluble receptors acting as
molecular traps emphasizes the need for tight control of the IL-1
system, which mediates potentially devastating local and systemic
inflammatory reactions.
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